23957-21-3

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-2,6-DIMETHOXYBENZENAMINE is utilized as a key intermediate in the synthesis of various medicines, contributing to the development of new therapeutic agents. Its unique chemical structure allows it to be a building block in the creation of diverse pharmaceutical compounds.
Used in Dye Production:
In the dye industry, 4-BROMO-2,6-DIMETHOXYBENZENAMINE is employed as a precursor for the production of different types of dyes. Its chemical properties enable it to contribute to the color characteristics and stability of the dyes produced.
Used in Research and Development:
4-BROMO-2,6-DIMETHOXYBENZENAMINE is also used in research and development within the pharmaceutical sector. It serves as a valuable compound for scientists to study and understand its potential applications, interactions, and effects in the context of drug discovery and design.

InChI:InChI=1/C8H10BrNO2/c1-11-6-3-5(9)4-7(12-2)8(6)10/h3-4H,10H2,1-2H3

Upstream product

• 815632-47-4 5-bromo-1,3-dimethoxy-2-nitrobenzene 
• 2734-70-5 2,6-dimethoxyaniline 
• 20469-65-2 1-bromo-3,5-dimethoxybenzene 

Downstream Products

• 427886-20-2 5-bromo-2-chloro-1,3-dimethoxybenzene 
• 1037082-67-9 5-bromo-2-iodo-1,3-dimethoxy-benzene 
• 1443648-11-0 (E)-1,2-bis(4-bromo-2,6-dimethoxyphenyl)diazene 
• 1009344-86-8 N-(4-Bromo-2,6-dimethoxy-phenyl)-3,3-dimethyl-butanamide 
• 482627-49-6 1,4-Bis[5-[3,5-dimethoxy-4-(1-pyrrolidinyl)phenyl]-pyridin-2-yl]hexahydro-1,4-diazepine 
• 482627-48-5 1,4-bis[5-(4-dimethylamino-3,5-dimethoxyphenyl)-2-pyridyl]hexahydro-1,4-diazepine 

Relevant academic research and scientific papers

Active ester functionalized azobenzenes as versatile building blocks

Azobenzenes are important molecular switches that can still be difficult to functionalize selectively. A high yielding Pd-catalyzed cross-coupling method under mild conditions for the introduction of NHS esters to azobenzenes and diazocines has been established. Yields were consistently high with very few exceptions. The NHS functionalized azobenzenes react with primary amines quantitatively. These amines are ubiquitous in biological systems and in material science.

RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.

Reinforced Topological Nanoassemblies: 2D Hexagon-Fused Wheel to 3D Prismatic Metallo-Lamellar Structure with Molecular Weight of 119 K Daltons

By a precise metallo-ligand design, the advanced coordination-driven self-assembly could succeed in the preparation of giant molecular weight of the metallo-architectures. However, the synthesis of a single discrete high-molecular-weight (>100 K Da) struc

ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS

Provided herein is technology relating to imaging agents for positron emission tomography (PET) and particularly, but not exclusively, to a gonadotropin-releasing hormone (GnRH) antagonist radiolabeled with positron emitting nuclides and to methods of visualizing GnRH receptors in the central nervous system by PET from administration of such compounds to warm-blooded animals for diagnostic purposes.

Photoswitching Azo compounds in vivo with red light

The photoisomerization of azobenzenes provides a general means for the photocontrol of molecular structure and function. For applications in vivo, however, the wavelength of irradiation required for trans-to-cis isomerization of azobenzenes is critical si

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

This invention provides a compound of formula IA where X═O or S; Y is O or S; q=1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. They are potentially usef